Literature DB >> 8293492

Osteoporosis in men.

A C Scane1, A M Sutcliffe, R M Francis.   

Abstract

Bone is lost with advancing age in men as in women, leading to an increased incidence of osteoporotic fractures of the fore-arm, vertebral body and femoral neck. By the ninth decade of life, 4% of men will have sustained a fore-arm fracture, 7% a vertebral fracture and 5% a femoral neck fracture. The absolute number of osteoporotic fractures is rising in men, because of the ageing population and an increase in the age-specific incidence of fractures. Even if the age-specific incidence of fractures stabilizes, demographic trends suggest that a further increase in the number of men with osteoporotic fractures is inevitable. Peak bone mass in men is influenced by race, hereditary, hormonal factors, physical activity and calcium intake during childhood and adolescence. Bone loss in men starts at about the age of 35 years and is regulated by genetic, endocrine, mechanical and nutritional factors. Secondary causes of osteoporosis may be detected in about 55% of men with vertebral crush fractures. The major causes are steroid therapy, hypogonadism, skeletal metastases, multiple myeloma, gastric surgery and anticonvulsant treatment. Hypogonadism is found in up to 20% of men with vertebral crush fractures, although the clinical features of testosterone deficiency may not always be present. Hypogonadal osteoporosis is associated with increased bone resorption and decreased mineralization, which is reversed by treatment with testosterone, leading to an increase in bone density. There is little published information on the treatment of primary osteoporosis in men. Although calcitonin, bisphosphonates and testosterone may be effective in the management of osteoporosis in men, confirmation is required in formal clinical trials.

Entities:  

Mesh:

Year:  1993        PMID: 8293492     DOI: 10.1016/s0950-3579(05)80081-0

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  13 in total

1.  Lack of biochemical hypogonadism in elderly Arab males with low bone mineral density disease.

Authors:  Haider M Al Attia; Krishnasamy Jaysundaram; Fouad Saraj
Journal:  Rheumatol Int       Date:  2009-06-12       Impact factor: 2.631

Review 2.  Bone loss in men.

Authors:  C Gennari; R Nuti
Journal:  Calcif Tissue Int       Date:  1996-01       Impact factor: 4.333

3.  Utility of biochemical screening in the context of evaluating patients with a presumptive diagnosis of osteoporosis.

Authors:  C Rajeswaran; J Spencer; J H Barth; S M Orme
Journal:  Clin Rheumatol       Date:  2006-05-11       Impact factor: 2.980

Review 4.  Background for studies on the treatment of male osteoporosis: state of the art.

Authors:  J M Kaufman; O Johnell; E Abadie; S Adami; M Audran; B Avouac; W B Sedrine; G Calvo; J P Devogelaer; V Fuchs; G Kreutz; P Nilsson; H Pols; J Ringe; L Van Haelst; J Y Reginster
Journal:  Ann Rheum Dis       Date:  2000-10       Impact factor: 19.103

Review 5.  Diseases affecting bone quality: beyond osteoporosis.

Authors:  Aasis Unnanuntana; Brian J Rebolledo; M Michael Khair; Edward F DiCarlo; Joseph M Lane
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

6.  Hip bone mineral density is improved by high-impact aerobic exercise in postmenopausal women and men over 50 years.

Authors:  L Welsh; O M Rutherford
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

7.  Ethnic and sex differences in bone marrow adipose tissue and bone mineral density relationship.

Authors:  W Shen; J Chen; M Gantz; M Punyanitya; S B Heymsfield; D Gallagher; J Albu; E Engelson; D Kotler; X Pi-Sunyer; S Shapses
Journal:  Osteoporos Int       Date:  2011-12-16       Impact factor: 4.507

Review 8.  The pathogenesis, treatment and prevention of osteoporosis in men.

Authors:  Leif Mosekilde; Peter Vestergaard; Lars Rejnmark
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

9.  Low transforming growth factor-beta1 serum levels in idiopathic male osteoporosis.

Authors:  B Akinci; F Bayraktar; A Saklamaz; T Demir; S Yener; A Comlekci; M A Ozcan; L Kebapcilar; F Yuksel; S Yesil
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

10.  Weekly oral alendronic Acid in male osteoporosis.

Authors:  Paul D Miller; Thomas Schnitzer; Ronald Emkey; Eric Orwoll; Clifford Rosen; Mark Ettinger; Kristel Vandormael; Anastasia Daifotis
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.